TSI’s manufacturing license for HMB approved in China

8b3549eb-fd9d-477a-a822-a79fbc3f5980articleimage.jpg

21 Aug 2017 --- TSI Group (TSI) has announced the approval of the first and only CFDA (China Food and Drug Administration) Manufacturing License for beta-hydroxy-beta-methylbutyrate (HMB) production in China. TSI’s Jiangyin Pharmaceutical facility, a wholly owned TSI Group company, received this exclusive license to produce HMB for use in Chinese food products.

Additionally, CFDA approved TSI’s HMB for an expanded range of Novel Food categories, such as beverages, chocolates, candies and baked goods. This approval is in addition to the existing and approved Chinese HMB markets; Sports Nutrition and Foods for Special Medical Purpose (FSMP, or Medical Foods).

“With the two new approvals, TSI is effectively positioned as the market leader and the only HMB manufacturer in China authorized to both produce and sell HMB ingredients domestically to the Chinese food and functional food markets and ultimately to deliver on our mission of promoting muscle health and to enhance consumers’ active lifestyles in China and around the world,” Alisan Sullivan, Senior Brand and Operations Manager, Innovative Products Division at TSI USA Inc., tells NutritionInsight.

TSI states that China is a key market for its global muscle health growth strategy and its mission is to deliver muscle health benefits that enhance and maintain consumers’ healthy and active lifestyles.

“After nearly two decades in the market and supported by a vast body of efficacy data (over 50 published clinical studies), HMB is a well-known and established staple for a sports enthusiast in the US and in Europe. With the sports nutrition market growing at 9 to 12 percent globally, and faster growth rates within the emerging economies like China, we see a great potential for our broad portfolio of HMB-based innovative and proprietary ingredients,” says Sullivan.

“Similarly, the general consumer awareness for HMB is growing fast, propelled by flagship products promoting muscle health and active lifestyle for elderly,” she adds.

“These recent regulatory approvals are significant milestones for all of us at TSI, the door is now wide open for us to deliver TSI’s world class HMB products to one of the fastest growing markets in the world – China,” concludes Larry Kolb, President, TSI Group. “We know HMB can make a difference in people’s daily lives and are excited for the opportunity to positively impact muscle health for millions of Chinese consumers – from athletes of all kinds to aging adults.”

By Paul Creasy

RELATED ARTICLES
Homepicture

Bayn Europe sets up subsidiary in China for sugar reduction

15 Jan 2018 Bayn Europe AB has signed a joint venture ...

Homepicture

Nuritas raises €16m in Series A funding

21 Dec 2017 Nuritas has announced the close of a circa ...

Homepicture

Nutrition industry “feels positive” about new EU rules for novel foods: survey

19 Dec 2017 According to research by the organizers of ...

Homepicture

Seventure Partners’ microbiome portfolio nears critical milestones 

18 Dec 2017 Seventure Partners, one of Europe’s ...